SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-008144
Filing Date
2024-05-14
Accepted
2024-05-14 16:30:52
Documents
84
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nrxp-20240331x10q.htm   iXBRL 10-Q 1412632
2 EX-31.1 nrxp-20240331xex31d1.htm EX-31.1 19707
3 EX-31.2 nrxp-20240331xex31d2.htm EX-31.2 16979
4 EX-32.1 nrxp-20240331xex32d1.htm EX-32.1 7493
5 EX-32.2 nrxp-20240331xex32d2.htm EX-32.2 6130
6 GRAPHIC nrxp-20240331x10q001.jpg GRAPHIC 72207
7 GRAPHIC nrxp-20240331x10q002.jpg GRAPHIC 48140
  Complete submission text file 0001558370-24-008144.txt   7741035

Data Files

Seq Description Document Type Size
8 EX-101.SCH nrxp-20240331.xsd EX-101.SCH 77458
9 EX-101.CAL nrxp-20240331_cal.xml EX-101.CAL 31857
10 EX-101.DEF nrxp-20240331_def.xml EX-101.DEF 335455
11 EX-101.LAB nrxp-20240331_lab.xml EX-101.LAB 485803
12 EX-101.PRE nrxp-20240331_pre.xml EX-101.PRE 484351
88 EXTRACTED XBRL INSTANCE DOCUMENT nrxp-20240331x10q_htm.xml XML 1065693
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38302 | Film No.: 24944929
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)